Epizyme (EPZM), which ended its first day of trading Friday up 40% from its initial $15 price,...


Epizyme (EPZM), which ended its first day of trading Friday up 40% from its initial $15 price, briefly broke the $30 mark on Monday before ending the day +21.75%. It's the third biotech IPO to quickly grow 50% since April, the others being Chimerix (CMRX) and Omthera (OMTH) - in the latter case due to the quick buyout offer from AstraZeneca.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs